More than a decade after AstraZeneca appeared to give up hope of using zibotentan to treat prostate cancer, the endothelin receptor antagonist has received a new lease on life as a combo treatment for chronic kidney disease.
Lexeo Therapeutics has disclosed plans to join the coveted ranks of biotechs raking in nine figures from their Nasdaq offering, despite downsizing its ambitions over the past few days.
After achieving a positive outcome in a preliminary look at a phase 1/2 trial for a solid tumor candidate, Kronos Bio is restructuring and cutting staff.
Convert more DNA into sequenceable library for enhanced sensitivity — particularly with cfDNA samples and ctDNA detection. Prepare highly complex libraries in under 2 hours from as little as 500 pg. Explore the data.
After securing the first-ever approval for an oral microbiome therapy in April, Seres Therapeutics is facing some tough choices, resulting in a restructuring that will claim 41% of staff.
Locanabio will close up shop by the end of the year as a tough market for biotechs claims another company that had been working on developing RNA medicines for rare diseases such as Duchenne muscular dystrophy.
While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more.
Pfizer is cutting roughly 200 positions at its Kalamazoo site following a review of demand for its COVID-19 vaccine and antiviral Comirnaty and Paxlovid.
Inari Medical has signed on to a $415 million deal to acquire LimFlow, just weeks after the company received FDA approval for its minimally invasive approach to re-establish oxygenated blood flow in the legs of people potentially facing amputation.
The Biden administration Thursday finalized policy changes for Medicare reimbursements in 2024 that will cut payments to physicians by 1.25% compared to 2023.
Even before a potential label expansion, the gene therapy Elevidys has raked in around $69 million since its launch. Earlier this week, the company said that a pivotal trial on the medicine failed to reach its primary endpoint. But Sarepta plans to seek a label expansion for the DMD gene therapy anyway.
Merck KGaA is in-licensing a PARP1 inhibitor from Hengrui. Novartis said an ex-employee who recently jumped to Takeda took sensitive files. The FDA approved Coherus and Junshi's China-made PD-1 inhibitor toripalimab. And more.
While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more.
This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders.
Presented by Blue Matter, strategic consultants in the life sciences
From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level.
Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development.
Sponsored by: Thermo Scientific™ Production Chemicals and Services
